(BHVN) Biohaven Pharmaceutical - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NYSE (USA) | Market Cap: 1.278m USD | Total Return: -38.8% in 12m
Avg Turnover: 17.2M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 44.8% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
Biohaven Ltd. is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut. The firm specializes in the discovery and development of therapies targeting neuroscience, immunology, and oncology. Its portfolio is diversified across multiple stages of clinical development, including Phase 3 candidates for Parkinson’s disease and focal epilepsy, alongside various Phase 2 programs for obesity, pain disorders, and advanced tumors.
The biotechnology sector typically operates on a high-risk, research-intensive business model where value is driven by clinical trial milestones and regulatory approvals. Biohaven utilizes a pipeline-in-a-product strategy, investigating specific molecular platforms across a broad range of indications to maximize potential market reach. Investors may find additional data points and valuation metrics on ValueRay to support further due diligence. The company also maintains an extensive preclinical pipeline focusing on neurodegenerative diseases and immune-mediated conditions.
- Positive Phase 3 readout for Opakalim in focal epilepsy validates late-stage pipeline
- BHV-1300 clinical data determines competitive standing in high-value immunology markets
- Progression of BHV-8000 through Phase 3 trials impacts long-term neuroscience valuation
- Research and development expenses for diverse pipeline necessitate future capital raises
- Successful expansion into obesity and oncology indications drives long-term revenue potential
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -1.18 > 0.02 and ΔFCF/TA 55.20 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -1.27 > 3% & CFO -594.2m > Net Income -647.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (147.6m) vs 12m ago 44.80% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.84%; Δ -0.84% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.72 (Total Current Assets 385.6m - Total Current Liabilities 52.1m) / Total Assets 466.4m |
| B: -4.75 (Retained Earnings -2.22b / Total Assets 466.4m) |
| C: -1.43 (EBIT TTM -660.6m / Avg Total Assets 462.7m) |
| D: -0.22 (Book Value of Equity -73.9m / Total Liabilities 336.9m) |
| Altman-Z'' = -20.61 = D |
As of May 24, 2026, the stock is trading at USD 9.45 with a total of 1,439,359 shares traded.
Over the past week, the price has changed by +7.88%,
over one month by -11.52%,
over three months by -18.39% and
over the past year by -38.76%.
Biohaven Pharmaceutical has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy BHVN.
- StrongBuy: 11
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.8 | 130.3% |
Revenue TTM = 0.0 USD
EBIT TTM = -660.6m USD
EBITDA TTM = -652.5m USD
Long Term Debt = 241.9m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 324.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 44.3m
Net Debt = -23.3m USD (calculated: Debt 324.5m - CCE 347.8m)
Enterprise Value = 1.25b USD (1.28b + Debt 324.5m - CCE 347.8m)
Interest Coverage Ratio = unknown (Ebit TTM -660.6m / Interest Expense TTM 0.0)
EV/FCF = -2.28x (Enterprise Value 1.25b / FCF TTM -550.3m)
FCF Yield = -43.85% (FCF TTM -550.3m / Enterprise Value 1.25b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.14m) / Revenue TTM)
Tobins Q-Ratio = 2.69 (Enterprise Value 1.25b / Total Assets 466.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 324.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -521.8m (EBIT -660.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.17 (Total Current Assets 385.6m / Total Current Liabilities 62.5m)
Debt / Equity = 2.51 (Debt 324.5m / totalStockholderEquity, last quarter 129.5m)
Debt / EBITDA = 0.04 (negative EBITDA) (Net Debt -23.3m / EBITDA -652.5m)
Debt / FCF = 0.04 (negative FCF - burning cash) (Net Debt -23.3m / FCF TTM -550.3m)
Total Stockholder Equity = 74.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -140.0% (out of range, set to none)
RoE = -28.29% (Net Income TTM -647.7m / Total Stockholder Equity 2.29b)
RoCE = -26.09% (EBIT -660.6m / Capital Employed (Equity 2.29b + L.T.Debt 241.9m))
RoIC = -133.8% (out of range, set to none) (NOPAT -521.8m / Invested Capital 390.0m)
WACC = 9.75% (E(1.28b)/V(1.60b) * Re(12.23%) + D(324.5m)/V(1.60b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 31.34%
[DCF] Fair Price = unknown (Cash Flow -550.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.54 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.64 | Chg30d=-2.22% | Revisions=+14% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.59 | Chg30d=-1.45% | Revisions=+14% | Analysts=6
EPS current Year (2026-12-31): EPS=-2.49 | Chg30d=-4.70% | Revisions=+14% | GrowthEPS=+55.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.98 | Chg30d=-1.64% | Revisions=+14% | GrowthEPS=+20.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +14%